Related Experiment Videos
Lysyl oxidase expression in bronchogenic carcinoma
Amy R Woznick1, Amy L Braddock, Mohanpal Dulai
1Department of Surgery, William Beaumont Hospital Research Institute, 3811 W. Thirteen Mile Rd., Royal Oak, MI 48073-6769, USA.
American Journal of Surgery
|March 29, 2005
Summary
Lysyl oxidase (LOX) expression decreases with advancing lung cancer stage. This suggests LOX may play a role in tumor invasion and metastasis in bronchogenic carcinoma.
Area of Science:
- Biochemistry
- Oncology
- Molecular Biology
Background:
- Lysyl oxidase (LOX) is crucial for extracellular matrix cross-linking.
- Altered LOX expression is observed in various cancers.
- Previous research indicates differential LOX expression in tumor stroma.
Purpose of the Study:
- To investigate the relationship between lysyl oxidase expression and tumor stage in bronchogenic carcinoma.
- To test the hypothesis that LOX mRNA and protein levels decrease as lung cancer progresses.
Main Methods:
- Analyzed tumor specimens from 17 patients with bronchogenic carcinoma.
- Quantified lysyl oxidase mRNA using real-time polymerase chain reaction.
- Assessed lysyl oxidase protein expression via immunohistochemistry.
Main Results:
- Demonstrated a 3.4-fold decrease in lysyl oxidase mRNA levels from Stage I to Stage IV lung cancer.
- Observed corresponding decreases in lysyl oxidase protein expression.
- Found a graded reduction in LOX expression correlating with tumor progression.
Conclusions:
- Lysyl oxidase expression levels correlate with the invasive and metastatic potential of lung cancer.
- Findings support the role of LOX in bronchogenic carcinoma progression.
- LOX may serve as a potential biomarker for lung cancer invasiveness.